Protia Highlights CE-IVDR-Certified Allergy and Autoimmune Diagnostic Tests

By LabMedica International staff writers
Posted on 19 Nov 2026

Protia (South Korea) is showcasing its in vitro diagnostic (IVD) solutions at MEDICA 2026, held November 16–19 in Düsseldorf, Germany. The company is highlighting its allergy and autoimmune disease testing portfolio, including the Protia Allergy-Q 192D and Allergy-Q 64D panels and Protia ANA Profile 18, which recently received European certification under the In Vitro Diagnostic Regulation (IVDR). The exhibit also features veterinary allergy testing and antimicrobial susceptibility testing solutions, reflecting Protia’s efforts to expand its presence in international diagnostic markets.

Among the featured products are the Protia Allergy-Q 192D and Allergy-Q 64D multiplex allergy diagnostic panels. The Allergy-Q 192D enables simultaneous testing for 176 allergens, while the Allergy-Q 64D incorporates component-resolved diagnostics (CRD) technology to support allergy testing, including the evaluation of reactions to antibiotics. Both products are designed to assess allergic sensitization through multiplex testing methods.


Image: Protia is highlighting its allergy and autoimmune disease testing products at MEDICA 2026 in Hall 1, Stand B07 (Photo courtesy of Protia)

Protia is also presenting its ANA Profile 18 panel, which simultaneously detects autoantibodies against 18 proteins associated with systemic autoimmune diseases. The assay supports the evaluation of conditions such as systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, and inflammatory myopathies. The three diagnostic products received CE-IVDR certification on November 6, 2026, following an assessment of the company's quality management system and technical documentation by European notified body TÜV SÜD Product Service GmbH.

In addition to its human immunodiagnostic products, Protia is exhibiting veterinary allergy testing solutions and antimicrobial susceptibility testing technologies. These offerings extend the company's diagnostic portfolio to animal health and testing applications that support antimicrobial treatment selection.

Protia currently exports its products to approximately 90 countries through a network of around 100 overseas distributors. Through its participation at MEDICA 2026, the company is seeking to strengthen partnerships with hospitals, laboratories, and distributors across Europe, the Middle East, Southeast Asia, Latin America, and Africa, supported by its recent European regulatory certifications.

Related Links
Protia


Latest Medica 2026 News